Top Markets
#1 The Bitcoin Bull The Bitcoin Bull +33.12%
#2 DogBull DogBull +31.59%
#3 Siacoin Siacoin +27.39%
#4 Merlin's Seal BTC Merlin's Seal BTC +25.80%
#5 Ontology Gas Ontology Gas +21.33%
#6 Cash Cat Cash Cat +20.65%
#7 Pons Pons +19.03%
#8 MarsCoin MarsCoin +16.36%
#9 Akedo Akedo +11.45%
#10 Uniswap Uniswap +11.35%
Coin of the day
The Bitcoin Bull The Bitcoin Bull
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Egetis Therapeutics AB (publ) Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX
Clasificación en acciones #14551
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to... Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Precio por acción
$0.87679425
Última sincronización: 2026-08-31
Capitalización bursátil
$407.66M
Cambio (1 día)
-1.88%
Cambio (1 año)
58.03%
País
SE
Comercio Egetis Therapeutics AB (publ) (EGTX)

Categoría

Healthcare
Ingresos de Egetis Therapeutics AB (publ) (EGTX)
Ingresos en Sep 2026 TTM: 0
Según los últimos informes financieros de Egetis Therapeutics AB (publ), los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Egetis Therapeutics AB (publ) desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH